Hill-Rom (HRC) Receives a Buy from Needham


Needham analyst Michael Matson reiterated a Buy rating on Hill-Rom (NYSE: HRC) today and set a price target of $108. The company’s shares opened today at $89.39.

Matson observed:

“HRC beat consensus F4Q18 revenue and EPS. Management provided below-consensus FY19 revenue and above-consensus FY19 EPS guidance. Organic revenue growth was stable at 4% in F4Q18 vs. 4% in F3Q18. Margins increased significantly Y/Y with adjusted gross margin up 30 bps and adjusted operating margin up 120 bps. Given HRC’s new product-driven revenue growth acceleration and strong margin performance from cost reductions and portfolio management, we believe HRC shares should trade more in line with peers (2019E P/E of 17.3x vs. small/mid-cap value peers at 22.1x) and we reiterate our Buy rating.”

According to TipRanks.com, Matson is a 5-star analyst with an average return of 11.6% and a 62.3% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Cardiovascular Systems, and Zimmer Biomet Holdings.

Currently, the analyst consensus on Hill-Rom is a Moderate Buy with an average price target of $104.

See today’s analyst top recommended stocks >>

The company has a one-year high of $98.96 and a one-year low of $75.21. Currently, Hill-Rom has an average volume of 467.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Hill-Rom Holdings, Inc. is a medical technology company, which focuses on patient care solutions that improve clinical and economic outcomes. It operates through three segments: Patient Support System, Front Line Care, and Surgical Solutions.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts